Particle.news
Immunotherapy Chemotherapy Clinical Trials Patient Support Palliative Care Mental Health Cancer Survivorship Prostate Cancer CAR T-cell Therapy Exercise Benefits Synovial Sarcoma Remission Personalized Medicine Therapeutic Vaccines Childhood Cancer Registry Kate Middleton's Health Cancer Advocacy Waiting Times Royal Patronage Royal Marsden Hospital Patient Experience Weight-loss Medications Kidney Cancer Colon Cancer Complications Targeted Drug Delivery Frozen Section Procedure Therapeutic Strategies Royal Family Health Issues Cancer Patient Care Melanoma Melanoma Vaccine Radioactive Iodine Therapy Cancer Immunotherapy Financial Toxicity Physical Activity Ferroptosis Inhibitors Immunotherapy Resistance T-cell Therapy Solid Tumors Misinformation Patient Advocacy Hormone Therapy Esophageal Adenocarcinoma Patient Care Chemotherapy Drugs Therapeutics Immunotherapy Efficacy Genetics iNKT Cell Therapy Royal Family Health Patient Support Services Survivorship Medical Technology Cancer Awareness End-of-Life Care Cancer Vaccines Proton Therapy CD40 Agonist Antibodies Radiotherapy Awareness Cancer Stem Cells Pain Management Mind-Body Therapies HPV-positive Throat Cancer Nutrition Therapy Therapeutic Cancer Vaccines Day Care Cancer Centres Bureaucracy in Healthcare Exercise and Cancer Theranostics Access to Treatment Ongoing Treatment Recovery Surgical Technology Surgical Intervention Surgical Techniques Performance Metrics Lung Cancer Vaccine Alternative Treatments Royal Family Health Updates Genomic Profiling CAR-T Therapy Lung Transplant Biologics HER2-targeted Therapy Chronic Pain
The Nature Nanotechnology study introduces NICER, a dual-target design that authors say requires further safety evaluation before clinical translation.
